Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Abstract 6709: NF1 mutations in lung adenocarcinoma preclinical models and potential targeted therapies: The crucial role of the RAS-MAPK pathway

Jean-Stephane Giraud, Doriane Gorret, Manuela Ye, Dominique Lallemand, William C. Reinhold, Didier Decaudin, Ingrid Laurendeau, Eric Pasmant, Camille Tlemsani

Cancer Res (2025) 85 (8_Supplement_1): 6709.

https://doi.org/10.1158/1538-7445.AM2025-6709

Published: 21 April 2025

View article titled, Abstract 6709: NF1 mutations in lung adenocarcinoma preclinical models and potential targeted therapies: The crucial role of the RAS-MAPK pathway

Journal Articles

Abstract A051 Genome-wide CRISPR/Cas9 library screening identified TP53 as a critical driver for resistance to EZH2 inhibitor in rhabdoid tumors

Céline Chauvin, Tiphaine Hery, Rachida Bouarich, Fariba Nemati, Diego Teyssonneau, Camille Fouassier, Chiara Giudiceandrea, Zhi-Yan Han, Sakina Zaidi, Didier Surdez, Sergio Roman-Roman, Didier Decaudin, Raphaël Margueron, Franck Bourdeaut

Cancer Res (2024) 84 (17_Supplement): A051.

https://doi.org/10.1158/1538-7445.PEDIATRIC24-A051

Published: 05 September 2024

View article titled, Abstract A051 Genome-wide CRISPR/Cas9 library screening identified TP53 as a critical driver for resistance to EZH2 inhibitor in rhabdoid tumors

Journal Articles

Abstract 4678: Characterization of a PDX panel covering molecular diversity of non-small cell lung cancer to accelerate the development of precision therapy

Delphine Nicolle, Laura Brulle-Soumare, Katell Mevel, Ludovic Bigot, Tala Tayoun, Benjamin Besse, Françoise Farace, Luc Friboulet, Didier Decaudin, Erwan Corcuff, Anaïs Joachim, Bernard Malissen, Ana Zarubica, Hervé Luche, Jean-Gabriel Judde, Olivier Deas

Cancer Res (2023) 83 (7_Supplement): 4678.

https://doi.org/10.1158/1538-7445.AM2023-4678

Published: 04 April 2023

View article titled, Abstract 4678: Characterization of a PDX panel covering molecular diversity of non-small cell lung cancer to accelerate the development of precision therapy

Journal Articles

Abstract 4677: A preclinical platform of breast cancer PDX and derived cellular models as a tool for pharmacological screening and functional studies

Delphine Nicolle, Aurore Gorce, Marie Tavernier, Elisabetta Marangoni, Didier Decaudin, Christophe Ginestier, Emmanuelle Charafe-Jaufret, Judith Passildas, Nina Robin, Robert Clarke, Erwan Corcuff, Anaïs Joachim, Bernard Malissen, Ana Zarubica, Hervé Luche, Jean-Gabriel Judde, Olivier Déas

Cancer Res (2023) 83 (7_Supplement): 4677.

https://doi.org/10.1158/1538-7445.AM2023-4677

Published: 04 April 2023

View article titled, Abstract 4677: A preclinical platform of breast cancer PDX and derived cellular models as a tool for pharmacological screening and functional studies

Journal Articles

Abstract 4031: PRMT1 regulates EGFR and Wnt signaling pathways and is a promising target for combinatorial treatment of breast cancer

Samyuktha Suresh, Solène Huard, Fariba Némati, Rayan Dakroub, André Nicolas, Didier Meseure, Didier Decaudin, Sergio Roman-Roman, Thierry Dubois

Cancer Res (2022) 82 (12_Supplement): 4031.

https://doi.org/10.1158/1538-7445.AM2022-4031

Published: 15 June 2022

View article titled, Abstract 4031: PRMT1 regulates EGFR and Wnt signaling pathways and is a promising target for combinatorial treatment of breast cancer

Journal Articles

Abstract LB567: Dramatic in vivo efficacy of the EZH2-inhibitor tazemetostat in PBRM1-mutated human chordoma xenograft

Cancer Res (2022) 82 (12_Supplement): LB567.

https://doi.org/10.1158/1538-7445.AM2022-LB567

Published: 15 June 2022

View article titled, Abstract LB567: Dramatic in vivo efficacy of the EZH2-inhibitor tazemetostat in PBRM1-mutated human chordoma xenograft

Journal Articles

Abstract 1685: The EurOPDX Research Infrastructure: Supporting European and worldwide cancer research with patient-derived xenografts

Cancer Res (2020) 80 (16_Supplement): 1685.

https://doi.org/10.1158/1538-7445.AM2020-1685

Published: 15 August 2020

View article titled, Abstract 1685: The EurOPDX Research Infrastructure: Supporting European and worldwide cancer research with patient-derived xenografts

Journal Articles

Abstract 5782: Selumetinib-based therapy in uveal melanoma patient-derived xenografts

Didier Decaudin, Rania EL Botty, Béré Diallo, Gerald Massonnet, Justine Fleury, Adnan Naguez, Marine Dubois, Emma J. Davies, Aaron Smith, Joanne Wilson, Colin Howes, Paul Smith, Nathalie Cassoux, Pascale Mariani, Sophie Piperno-Neumann, Sergio Roman Roman, Fariba Nemati

Cancer Res (2018) 78 (13_Supplement): 5782.

https://doi.org/10.1158/1538-7445.AM2018-5782

Published: 01 July 2018

View article titled, Abstract 5782: Selumetinib-based therapy in uveal melanoma patient-derived xenografts

Journal Articles

Abstract 1718: Tumor immune gene profile before and after various targeted therapies in NSCLC PDXs

Elodie Montaudon, Sophie Vacher, Wilfrid Richer, Ahmed Dahmani, Caroline Guibaudet, Olivier Déas, Stefano Cairo, Ludmilla De Plater, Marine Dubois, Fariba Némati, Christine Sedlik, Jean-Gabriel Judde, Nicolas Girard, Ivan Bieche, Eliane Piaggio, Didier Decaudin

Cancer Res (2018) 78 (13_Supplement): 1718.

https://doi.org/10.1158/1538-7445.AM2018-1718

Published: 01 July 2018

View article titled, Abstract 1718: Tumor immune gene profile before and after various targeted therapies in NSCLC PDXs

Journal Articles

Abstract 3904: PEP-010, a cell penetrating & interfering peptide as a new therapeutic approach in breast cancer

Sophie Lebel-Binay, Fariba Nemati, Leticia Dominguez-Berrocal, Justine Fleury, Adnan Naguez, Didier Decaudin, Angelita Rebollo

Cancer Res (2018) 78 (13_Supplement): 3904.

https://doi.org/10.1158/1538-7445.AM2018-3904

Published: 01 July 2018

View article titled, Abstract 3904: PEP-010, a cell penetrating & interfering peptide as a new therapeutic approach in breast cancer

Journal Articles

Abstract 2087: The MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) appears as an efficient targeted therapy when used in an adjuvant setting in patient-derived xenografts of uveal melanoma

Béré Diallo, Gerald Massonnet, Rania El-Botty, Chloé Raymondie, Guillaume Carita, Sergio Roman-Roman, Paul Smith, Emma Davies, Didier Decaudin, Fariba Némati

Cancer Res (2016) 76 (14_Supplement): 2087.

https://doi.org/10.1158/1538-7445.AM2016-2087

Published: 15 July 2016

View article titled, Abstract 2087: The MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) appears as an efficient targeted therapy when used in an adjuvant setting in patient-derived xenografts of uveal melanoma

Journal Articles

Abstract 3027: Dual inhibition of PKC and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma

Guillaume Carita, Estelle Frisch Dit Leitz, Ahmed Dahmani, Chloe Raymondie, Nathalie Cassoux, Sophie Piperno-Neumann, Fariba Némati, Ensar Halilovic, Sebastien Jeay, Andrew Wylie, Caroline Emery, Sergio Roman-Roman, Marie Schoumacher, Didier Decaudin

Cancer Res (2016) 76 (14_Supplement): 3027.

https://doi.org/10.1158/1538-7445.AM2016-3027

Published: 15 July 2016

View article titled, Abstract 3027: Dual inhibition of PKC and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma

Journal Articles

Abstract 2559: Optimisation of EGFR TKI efficiency wild-type EGFR lung cancer

Judith Raimbourg, Mathilde Cabart, Marie-Pierre Joalland, Didier Decaudin, Ludmilla Deplater, Didier Lanoe, Jean-Yves Douillard, Jaafar Bennouna, François Vallette, Lisenn Lalier

Cancer Res (2015) 75 (15_Supplement): 2559.

https://doi.org/10.1158/1538-7445.AM2015-2559

Published: 01 August 2015

View article titled, Abstract 2559: Optimisation of EGFR TKI efficiency wild-type EGFR lung cancer

Journal Articles

Abstract 2627: Use of xenografts for preclinical drug testing

Mark J. De Lange, Fariba Némati, Mieke Versluis, Martine J. Jager, Gre P.M. Luyten, Didier Decaudin, Pieter A. van der Velden

Cancer Res (2014) 74 (19_Supplement): 2627.

https://doi.org/10.1158/1538-7445.AM2014-2627

Published: 01 October 2014

View article titled, Abstract 2627: Use of xenografts for preclinical drug testing

Journal Articles

Abstract 3915: Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target

Nabil Amirouchene-Angelozzi, Fariba Nemati, David Gentien, May-Linda Lepage, André Nicolas, Jordan Madic, Amaury Dumont, Guillaume Carita, Jaques Camonis, Laurence Desjardins, Nathalie Cassoux, Sophie Piperno-Neumann, Pascale Mariani, Xavier Sastre, Didier Decaudin, Sergio Roman-Roman

Cancer Res (2014) 74 (19_Supplement): 3915.

https://doi.org/10.1158/1538-7445.AM2014-3915

Published: 01 October 2014

View article titled, Abstract 3915: Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target

Journal Articles

Abstract 4428: Pre-clinical studies of the therpaeutic effect of a PARP inhibitor combined with radiotherapy for breast cancer treatment.

Frederic Pouzoulet, Victor Pernin, Christophe Roulin, Hélène Alcade, Franck Assayag, Frédérique Mégnin-Chanet, Laurence Vaslin-Lepetit, Sophie Heinrich, Florence Mahuteau-Betzer, Aurélie Thuleau, Tomasz Zaremba, Vincent Favaudon, Elisabetta Marangoni, Youlia Kirova, Alain Fourquet, Janet Hall, Didier Decaudin

Cancer Res (2013) 73 (8_Supplement): 4428.

https://doi.org/10.1158/1538-7445.AM2013-4428

Published: 15 April 2013

View article titled, Abstract 4428: Pre-clinical studies of the therpaeutic effect of a PARP inhibitor combined with radiotherapy for breast cancer treatment.

Journal Articles

Abstract LB-263: Identification of gene-expression modifications related to the tumor engraftment in patient-derived xenograft models of solid tumors.

Cécile Laurent, Elisabetta Marangoni, Philippe Hupé, Fariba Némati, Nathalie Cassoux, David Gentien, Oumou Goundiam, Virginie Dangles-Marie, Sophie Piperno-Neumann, Pascale Mariani, Didier Decaudin, Laurence Desjardins, Xavier Sastre, Sergio Roman-Roman, Fabien Reyal

Cancer Res (2013) 73 (8_Supplement): LB-263.

https://doi.org/10.1158/1538-7445.AM2013-LB-263

Published: 15 April 2013

View article titled, Abstract LB-263: Identification of gene-expression modifications related to the tumor engraftment in patient-derived xenograft models of solid tumors.

Journal Articles

Abstract 85: Endocrine resistant luminal breast cancer xenografts are powerful models for the analysis of sensitivity to endocrine and everolimus treatments .

Paul H. Cottu, Thomas Bagarre, Jean-Jacques Fontaine, Franck Assayag, Sophie Richon, Sophie Chateau-Joubert, Aurélie Thuleau, Patricia de Cremoux, Khemaies Slimane, Didier Decaudin, Anne Vincent-Salomon, Ivan Bièche, Elisabetta Marangoni

Cancer Res (2013) 73 (8_Supplement): 85.

https://doi.org/10.1158/1538-7445.AM2013-85

Published: 15 April 2013

View article titled, Abstract 85: Endocrine resistant luminal breast cancer xenografts are powerful models for the analysis of sensitivity to endocrine and everolimus treatments .

Journal Articles

Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer

Cancer Res (2013) 73 (2): 813–823.

https://doi.org/10.1158/0008-5472.CAN-12-2633

Published: 16 January 2013

View article titled, Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer

Includes: Supplementary data

Journal Articles

Abstract LB-111: Mastospheres as a new 3D ex vivo breast cancer microtumors for preclinical drug testing

Sophie Richon, Paul Cottu, Louis-Bastien Weiswald, Jean-Marc Guinebretiere, Elisabetta Marangoni, Franck Assayag, Aurelie Thuleau, Dalila Labiod, Didier Decaudin, Dominique Bellet, Virginie Dangles-Marie

Cancer Res (2012) 72 (8_Supplement): LB-111.

https://doi.org/10.1158/1538-7445.AM2012-LB-111

Published: 15 April 2012

View article titled, Abstract LB-111: Mastospheres as a new 3D ex vivo breast cancer microtumors for preclinical drug testing

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 6709: NF1 mutations in lung adenocarcinoma preclinical models and potential targeted therapies: The crucial role of the RAS-MAPK pathway

Abstract A051 Genome-wide CRISPR/Cas9 library screening identified TP53 as a critical driver for resistance to EZH2 inhibitor in rhabdoid tumors

Abstract 4678: Characterization of a PDX panel covering molecular diversity of non-small cell lung cancer to accelerate the development of precision therapy

Abstract 4677: A preclinical platform of breast cancer PDX and derived cellular models as a tool for pharmacological screening and functional studies

Abstract 4031: PRMT1 regulates EGFR and Wnt signaling pathways and is a promising target for combinatorial treatment of breast cancer

Abstract LB567: Dramatic in vivo efficacy of the EZH2-inhibitor tazemetostat in PBRM1-mutated human chordoma xenograft

Abstract 1685: The EurOPDX Research Infrastructure: Supporting European and worldwide cancer research with patient-derived xenografts

Abstract 5782: Selumetinib-based therapy in uveal melanoma patient-derived xenografts

Abstract 1718: Tumor immune gene profile before and after various targeted therapies in NSCLC PDXs

Abstract 3904: PEP-010, a cell penetrating & interfering peptide as a new therapeutic approach in breast cancer

Abstract 2087: The MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) appears as an efficient targeted therapy when used in an adjuvant setting in patient-derived xenografts of uveal melanoma

Abstract 3027: Dual inhibition of PKC and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma

Abstract 2559: Optimisation of EGFR TKI efficiency wild-type EGFR lung cancer

Abstract 2627: Use of xenografts for preclinical drug testing

Abstract 3915: Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target

Abstract 4428: Pre-clinical studies of the therpaeutic effect of a PARP inhibitor combined with radiotherapy for breast cancer treatment.

Abstract LB-263: Identification of gene-expression modifications related to the tumor engraftment in patient-derived xenograft models of solid tumors.

Abstract 85: Endocrine resistant luminal breast cancer xenografts are powerful models for the analysis of sensitivity to endocrine and everolimus treatments .

Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer

Abstract LB-111: Mastospheres as a new 3D ex vivo breast cancer microtumors for preclinical drug testing

Email alerts

AACR Journals

Resources

AACR Journals
on Social Media

Update search

Email alerts

AACR Journals

Resources

AACR Journals on Social Media

This Feature Is Available To Subscribers Only

AACR Journals
on Social Media